KBC Group NV Acquires 2,132 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

KBC Group NV raised its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 40.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,356 shares of the biotechnology company’s stock after purchasing an additional 2,132 shares during the quarter. KBC Group NV’s holdings in Arrowhead Pharmaceuticals were worth $94,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ARWR. Avoro Capital Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 25.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company’s stock valued at $208,889,000 after purchasing an additional 2,222,223 shares in the last quarter. Norges Bank bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at $38,622,000. Farallon Capital Management LLC bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at $11,821,000. Two Sigma Investments LP increased its stake in Arrowhead Pharmaceuticals by 281.3% during the 4th quarter. Two Sigma Investments LP now owns 794,373 shares of the biotechnology company’s stock valued at $14,934,000 after purchasing an additional 586,062 shares in the last quarter. Finally, Slate Path Capital LP increased its stake in Arrowhead Pharmaceuticals by 7.1% during the 4th quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company’s stock valued at $98,362,000 after purchasing an additional 347,000 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on ARWR. Citigroup decreased their price target on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating for the company in a research note on Tuesday, May 13th. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, June 14th. Finally, Chardan Capital reiterated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $43.71.

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $16.84 on Tuesday. The firm has a market cap of $2.33 billion, a P/E ratio of -12.03, a PEG ratio of 19.75 and a beta of 0.93. The firm has a 50-day moving average of $15.51 and a 200 day moving average of $16.37. The company has a debt-to-equity ratio of 0.31, a quick ratio of 5.15 and a current ratio of 5.15. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $9.57 and a fifty-two week high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $2.81. The company had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same quarter in the previous year, the company posted ($1.02) EPS. On average, research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of the stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $11.49, for a total transaction of $583,692.00. Following the completion of the transaction, the chief executive officer owned 3,921,255 shares in the company, valued at approximately $45,055,219.95. This represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.